Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Sanborn · SciRah

Researcher profile · Semantic Scholar

R. Sanborn

Share profile

R. Sanborn — researcher profile on SciRah

h-index: 33
Works: 185
Citations: 7,578

Most-cited papers

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park, E. Haura, N. Leighl, P. Mitchell +30 more
2021Journal of Clinical Oncology552 citations Open access
Semantic Scholar
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
M. Nishio, F. Barlesi, H. West, S. Ball +16 more
2020Journal of Thoracic Oncology358 citations Open access
Semantic Scholar
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer
L. Horn, J. Whisenant, H. Wakelee, K. Reckamp +19 more
2019Journal of Thoracic Oncology167 citations Open access
Semantic Scholar
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
P. Ascierto, E. Lipson, R. Dummer, J. Larkin +18 more
2023Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
N. Leighl, H. Akamatsu, Sun M. Lim, Ying Cheng +44 more
2024Journal of Clinical Oncology105 citations Open access
Semantic Scholar
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
B. Cho, Dong-Wan Kim, A. Spira, Jorge E. Gomez +20 more
2023Nature Medicine103 citations Open access
Semantic Scholar
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
E. Haura, B. Cho, J. S. Lee, Ji-Youn Han +16 more
2019Journal of Clinical Oncology78 citations
Semantic Scholar
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
J. Bauml, B. Cho, Keunchil Park, K. Lee +16 more
202170 citations
Semantic Scholar
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
R. Sanborn, M. Pishvaian, M. Callahan, A. Weise +20 more
2022Journal for ImmunoTherapy of Cancer61 citations Open access
Semantic Scholar
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
V. Boni, M. Fidler, H. Arkenau, A. Spira +24 more
2022Clinical Cancer Research58 citations Open access
Semantic Scholar
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
M. Johnson, A. El-Khoueiry, Navid Hafez, N. Lakhani +10 more
2021Clinical Cancer Research57 citations Open access
Semantic Scholar
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
A. Berezhnoy, B. Sumrow, K. Stahl, Kalpana Shah +15 more
2020Cell Reports Medicine52 citations Open access
Semantic Scholar
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
C. Shu, K. Goto, Y. Ohe, B. Besse +15 more
2022Journal of Clinical Oncology47 citations
Semantic Scholar
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
D. Planchard, R. Sanborn, M. Negrao, A. Vaishnavi +1 more
2024npj Precision Oncology42 citations Open access
Semantic Scholar
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
K. Do, L. Chow, K. Reckamp, R. Sanborn +12 more
2021The Oncologist38 citations Open access
Semantic Scholar
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
B. Cho, K. Lee, E. Cho, D.-W. Kim +16 more
202038 citations Open access
Semantic Scholar
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers
R. Epstein, R. Weerasinghe, A. Parrish, J. Krenitsky +2 more
2021Journal of Medical Economics36 citations Open access
Semantic Scholar
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Keunchil Park, J. Sabari, E. Haura, C. Shu +14 more
2023Lung Cancer32 citations Open access
Semantic Scholar
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).
A. El-Khoueiry, M. Fakih, M. Gordon, A. Tsimberidou +16 more
2023Journal of Clinical Oncology32 citations
Semantic Scholar
OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
J. Sabari, C. Shu, K. Park, N. Leighl +20 more
202129 citations Open access
Semantic Scholar
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
H. Beltran, A. Dowlati, P. Jain, Melissa L. Johnson +9 more
2024Journal of Clinical Oncology28 citations
Semantic Scholar
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
R. Sanborn, O. Hamid, E. D. de Vries, P. Ott +9 more
2021Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
M. Shafique, T. Fisher, E. Evans, J. Leonard +17 more
2021Clinical Cancer Research27 citations
Semantic Scholar
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies
B. Fox, W. Urba, S. Jensen, D. Page +3 more
2023Clinical Cancer Research22 citations Open access
Semantic Scholar
1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
C. Shu, K. Goto, Y. Ohe, B. Besse +15 more
2021Annals of Oncology22 citations Open access
Semantic Scholar
Results of Lung Cancer Screening in the Community
J. Handy, M. Skokan, E. Rauch, S. Zinck +3 more
2020Annals of Family Medicine21 citations Open access
Semantic Scholar
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments
Mo Yang, Erin Mandal, Frank X. Liu, R. O'Hara +2 more
2024Frontiers in Oncology20 citations Open access
Semantic Scholar
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
N. Leighl, H. Akamatsu, Sun M. Lim, Ying Cheng +16 more
2024Journal of Clinical Oncology16 citations Open access
Semantic Scholar
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
A. Bullock, M. Fakih, M. Gordon, A. Tsimberidou +17 more
2023Annals of Oncology15 citations Open access
Semantic Scholar
CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.
M. Johnson, A. El-Khoueiry, Navid Hafez, N. Lakhani +7 more
202015 citations
Semantic Scholar
LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)
X. Le, J. Patel, E. Shum, R. Sanborn +13 more
2023Annals of Oncology13 citations
Semantic Scholar
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
D. Ruan, M. Lee, Yan-Hong Deng, Keun-Wook Lee +15 more
2023Journal of Clinical Oncology12 citations Open access
Semantic Scholar
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
A. Hollebecque, Juanita Lopez, S. Piha-Paul, A. Dowlati +11 more
2023Journal of Clinical Oncology11 citations
Semantic Scholar
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting.
G. Gerstner, S. Ramalingam, A. Lisberg, C. Farber +11 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer.
R. Sanborn, F. Schneiders, S. Senan, S. Gadgeel
2022American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting11 citations Open access
Semantic Scholar
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.
R. Cohen, G. Peoples, T. Kawashima, B. Arana +6 more
202111 citations
Semantic Scholar
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
A. El-Khoueiry, N. Tchekmedyian, R. Sanborn, J. Peguero +9 more
202011 citations
Semantic Scholar
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).
V. Boni, H. Burris, Joyce F. Liu, A. Spira +16 more
202011 citations
Semantic Scholar
375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC
M. Nishio, F. Barlesi, S. Ball, R. Bordoni +15 more
202010 citations Open access
Semantic Scholar
Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
R. Sanborn, N. Gabrail, N. Bhardwaj, M. Gordon +10 more
2019Immunology10 citations
Semantic Scholar
Abstract B005: A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
D. López, M. Barve, Judy S. Wang, A. Bullock +10 more
2019EGFR / Her210 citations
Semantic Scholar
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
N. Girard, B. Cho, A. Spira, C. Shu +16 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.
J. Luke, Manish R. Sharma, S. Chandana, I. Lugowska +13 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy.
S. Arnold, K. Chansky, M. Baggstrom, M. Thompson +8 more
2020Clinical Lung Cancer9 citations
Semantic Scholar
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)
R. Sanborn, R. Hauke, N. Gabrail, M. O'Hara +14 more
20209 citations Open access
Semantic Scholar
Abstract CT275: Phase 1 clinical update of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors
B. Carneiro, B. Garmezy, J. Hamm, R. Sanborn +9 more
2023Cancer Research8 citations
Semantic Scholar
1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Manish R. Sharma, R. Sanborn, G. Cote, J. Bendell +7 more
20208 citations Open access
Semantic Scholar
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
R. Sanborn, N. Gabrail, Benedito A Carneiro, M. O'Hara +12 more
2022Regular and Young Investigator Award Abstracts7 citations Open access
Semantic Scholar
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
B. Wilky, A. El-Khoueiry, A. Bullock, A. Tsimberidou +31 more
2022Regular and Young Investigator Award Abstracts7 citations Open access
Semantic Scholar
SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).
E. Garralda, R. Sanborn, A. Minchom, D. Davar +7 more
20217 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Spira×14
Invite
A. Spira — researcher profile on SciRah
J. Bauml×11
Invite
J. Bauml — researcher profile on SciRah
R. Knoblauch×10
Invite
R. Knoblauch — researcher profile on SciRah
B. Cho×10
Invite
B. Cho — researcher profile on SciRah

×9

Invite

J. Sabari — researcher profile on SciRah

Invite

M. Thayu — researcher profile on SciRah

Invite

John Xie — researcher profile on SciRah

A. El-Khoueiry×7

Invite

A. El-Khoueiry — researcher profile on SciRah

Invite

E. Haura — researcher profile on SciRah

Invite

J. Curtin — researcher profile on SciRah

Keunchil Park×5

Invite

Keunchil Park — researcher profile on SciRah

Invite

C. Shu — researcher profile on SciRah